Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload

Next Previous
X
Search
Trial Profile

Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deferiprone (Primary)
  • Indications Iron overload
  • Focus Adverse reactions
  • Acronyms TWICE
  • Sponsors ApoPharma

    • Most Recent Events

    • 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association
    • 21 Feb 2020 Status changed from active, no longer recruiting to completed.
    • 06 Feb 2020 This trial has been completed in Greece, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top